myo-inositol

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• anxiety [Possibly Ineffective]
• ARDS [Possibly Ineffective]
• bipolar disorder [Insufficient Evidence]
• child growth [Insufficient Evidence]
• depression [Possibly Ineffective]
• diabetes [Insufficient Evidence]
• diabetic neuropathy [Possibly Ineffective]
• dyslipidemia [Insufficient Evidence]
• erectile dysfunction [Insufficient Evidence]
• HTN [Insufficient Evidence]
• HTN, pregnancy-induced [Insufficient Evidence]
• hypothyroidism [Insufficient Evidence]
• infertility in patients of childbearing potential [Insufficient Evidence]
• insomnia [Insufficient Evidence]
• leukopenia, chemo-related [Insufficient Evidence]
• lithium-induced adverse effects [Insufficient Evidence]
• lung CA [Insufficient Evidence]
• mastalgia [Insufficient Evidence]
• metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
• metabolic syndrome [Possibly Effective]
• obesity [Insufficient Evidence]
• obsessive-compulsive disorder [Insufficient Evidence]
• panic disorder [Insufficient Evidence]
• polycystic ovary syndrome [Possibly Effective]
• postpartum complications [Insufficient Evidence]
• post-traumatic stress disorder [Insufficient Evidence]
• preterm labor prevention [Possibly Effective]
• psoriasis [Insufficient Evidence]
• retinopathy of prematurity [Possibly Ineffective]
• testosterone deficiency, age-related [Insufficient Evidence]
• trichotillomania [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

bipolar disorder, peds patients

[Insufficient Evidence]

Dose: 80 mg/kg/dose PO qd; Max: 2 g/dose; Info: for patients 5-12 yo; used with or without eicosapentaenoic acid

child growth

[Insufficient Evidence]

Dose: 4 g/day myo-inositol PO divided bid; Info: for use prior to conception and throughout pregnancy

diabetes mellitus, type 1

[Insufficient Evidence]

Dose: 1 g D-chiro-inositol PO qd; Info: used with folic acid and insulin

erectile dysfunction

[Insufficient Evidence]

Dose: 2 g myo-inositol PO bid

gestational diabetes prevention

[Insufficient Evidence]

Dose: 0.2-4 g myo-inositol PO qd; Alt: 2 g myo-inositol PO bid starting 1st trimester; Info: used with or without folic acid

HTN, pregnancy-induced

[Insufficient Evidence]

Dose: 2 g myo-inositol PO bid; Start: 1st trimester; Info: used with folic acid

hypothyroidism

[Insufficient Evidence]

Dose: 600-1200 mg PO qd; Alt: 600 mg myo-inositol PO qd; Info: used with selenium

infertility in patients of childbearing potential

[Insufficient Evidence]

Dose: 4 g myo-inositol PO qd starting 1-3mo before ICSI, continue until ovulation; Alt: 2 g myo-inositol PO bid starting day 3 of IVF cycle x2mo; 400 mg myo-inositol and 45 mg D-chiro-inositol PO tid; Info: used with or without folic acid

insomnia

[Insufficient Evidence]

Dose: 2 g myo-inositol PO qhs; Info: used with folic acid

leukopenia, chemo-related

[Insufficient Evidence]

Dose: 390 mg PO bid; Info: used with inositol hexaphosphate 4% gel topically to surgical site; start 2wk before adjuvant chemo regimen, continue until 2wk after last cycle

lithium-induced psoriasis

[Insufficient Evidence]

Dose: 6 g PO qd

mastalgia

[Insufficient Evidence]

Dose: apply 2.5 g gel topically qd; Start: day 10 of menstrual cycle, continue until day 25 of cycle x3mo; Info: product containing myo-inositol, boswellia, and betaine

metabolic dysfunction-associated steatotic liver disease

[Insufficient Evidence]

Dose: 4 g myo-inositol PO qd

metabolic syndrome

[Possibly Effective]

Dose: 2 g myo-inositol PO bid; Alt: 0.02 g D-chiro-inositol PO bid given 30min before meals

obesity

[Insufficient Evidence]

Dose: 0.6-4.45 g PO qd

obsessive-compulsive disorder

[Insufficient Evidence]

Dose: 18 g PO qd

panic disorder

[Insufficient Evidence]

Dose: 12-18 g PO qd

polycystic ovary syndrome

[Possibly Effective]

Dose: 2 g PO bid; Alt: 4 g myo-inositol PO qd; 1-1.2 g D-chiro-inositol PO qd; 550 mg myo-inositol and 13.8 mg D-chiro-inositol PO bid; 550 mg myo-inositol and 150 mg D-chiro-inositol PO bid; Info: often used with folic acid

postpartum complications

[Insufficient Evidence]

Dose: 4 g/day myo-inositol PO divided bid; Start: 1st trimester, continue throughout pregnancy

preterm labor prevention

[Possibly Effective]

Dose: 2 g myo-inositol PO bid; Alt: 1.1 g myo-inositol and 27.6 mg D-chiro-inositol PO qd; Info: for patients with gestational diabetes risk; used with folic acid

psoriasis

[Insufficient Evidence]

Dose: apply 40% cream topically qd-bid; Info: product containing amino-inositol and urea

testosterone deficiency, age-related

[Insufficient Evidence]

Dose: 600 mg D-chiro-inositol PO bid